The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course

Constantine S. Tam, Lynne V. Abruzzo, Katherine I. Lin, Jorge Cortes, Alice Lynn, Michael J. Keating, Deborah A. Thomas, Sherry Pierce, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 ± one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or ≥ 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated.

Original languageEnglish (US)
Pages (from-to)4171-4178
Number of pages8
JournalBlood
Volume113
Issue number18
DOIs
StatePublished - Nov 18 2009
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Delayed Diagnosis
Chromosomes
Chromosome Aberrations
Survival
Chromosomes, Human, Pair 17
Platelets
Cytogenetics
Hemoglobins
Clonal Evolution
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Diploidy
Platelet Count
Karyotype
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis : Applicability at the time of diagnosis and later during disease course. / Tam, Constantine S.; Abruzzo, Lynne V.; Lin, Katherine I.; Cortes, Jorge; Lynn, Alice; Keating, Michael J.; Thomas, Deborah A.; Pierce, Sherry; Kantarjian, Hagop; Verstovsek, Srdan.

In: Blood, Vol. 113, No. 18, 18.11.2009, p. 4171-4178.

Research output: Contribution to journalArticle

Tam, CS, Abruzzo, LV, Lin, KI, Cortes, J, Lynn, A, Keating, MJ, Thomas, DA, Pierce, S, Kantarjian, H & Verstovsek, S 2009, 'The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course', Blood, vol. 113, no. 18, pp. 4171-4178. https://doi.org/10.1182/blood-2008-09-178541
Tam, Constantine S. ; Abruzzo, Lynne V. ; Lin, Katherine I. ; Cortes, Jorge ; Lynn, Alice ; Keating, Michael J. ; Thomas, Deborah A. ; Pierce, Sherry ; Kantarjian, Hagop ; Verstovsek, Srdan. / The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis : Applicability at the time of diagnosis and later during disease course. In: Blood. 2009 ; Vol. 113, No. 18. pp. 4171-4178.
@article{a7b8b099898a4fd5b6ccac2d06fdc856,
title = "The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course",
abstract = "Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 ± one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or ≥ 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated.",
author = "Tam, {Constantine S.} and Abruzzo, {Lynne V.} and Lin, {Katherine I.} and Jorge Cortes and Alice Lynn and Keating, {Michael J.} and Thomas, {Deborah A.} and Sherry Pierce and Hagop Kantarjian and Srdan Verstovsek",
year = "2009",
month = "11",
day = "18",
doi = "10.1182/blood-2008-09-178541",
language = "English (US)",
volume = "113",
pages = "4171--4178",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis

T2 - Applicability at the time of diagnosis and later during disease course

AU - Tam, Constantine S.

AU - Abruzzo, Lynne V.

AU - Lin, Katherine I.

AU - Cortes, Jorge

AU - Lynn, Alice

AU - Keating, Michael J.

AU - Thomas, Deborah A.

AU - Pierce, Sherry

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2009/11/18

Y1 - 2009/11/18

N2 - Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 ± one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or ≥ 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated.

AB - Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 ± one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or ≥ 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated.

UR - http://www.scopus.com/inward/record.url?scp=66149113655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149113655&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-09-178541

DO - 10.1182/blood-2008-09-178541

M3 - Article

C2 - 19131547

AN - SCOPUS:66149113655

VL - 113

SP - 4171

EP - 4178

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -